Ambrx Biopharma (AMAM) Stock Price, News & Analysis

Company Overview

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Key Stats

• Today's Range: $28.00 to $28.00
• 50-Day Range: $27.70 to $28.00
• 52-Week Range: $6.55 to $28.15
• Volume: N/A
• Average Volume: 2.12 million shs
• Market Capitalization: $1.77 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMAM Stock Analysis - Frequently Asked Questions

When did Ambrx Biopharma IPO?

Ambrx Biopharma (AMAM) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen acted as the underwriters for the IPO.

What other stocks do shareholders of Ambrx Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ambrx Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Adobe (ADBE).

Company Calendar

• Today: 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NYSE:AMAM
• CIK: 1836056
• Web: ambrx.com
• Phone: 858-875-2400
• Fax: N/A
• Employees: 87
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.28
• Quick Ratio: 13.28

Sales & Book Value

• Annual Sales: $7.40 million
• Price / Sales: 238.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.05 per share
• Price / Book: 9.18

Miscellaneous

• Outstanding Shares: 63,150,000
• Free Float: 62,746,000
• Market Cap: $1.77 billion
• Optionable: Optionable
• Beta: -1.92